FDA Leadership in Turmoil—Trump’s Next Move?

President Trump has signed off on a plan to fire FDA Commissioner Marty Makary after less than 14 months on the job, revealing yet another battle between a government official attempting to maintain scientific standards and political pressure from industry lobbyists with direct access to the White House.

Story Snapshot

Trump approved firing plan for FDA Commissioner Makary following clashes over flavored e-cigarette approvals and drug rejections
Tensions escalated after Trump met with vaping industry executive and pressured Makary to fast-track fruit-flavored vape approvals
No termination date set as Trump could reverse decision, creating uncertainty that stalls critical FDA drug and product approvals
Makary’s resistance to industry pressure highlights growing concerns about corporate influence over public health decisions

White House Chaos Over FDA Leadership

President Trump has authorized a plan to remove FDA Commissioner Marty Makary from his position, according to multiple sources familiar with the matter. The Wall Street Journal first reported the development on May 8, 2026, though Trump himself denied knowledge when questioned by reporters the following day. This contradictory messaging exemplifies the chaotic decision-making that frustrates Americans across the political spectrum who expect transparency and consistency from their government. Despite the approved firing plan, no termination date has been established, leaving the FDA in limbo during a critical period for drug approvals and public health decisions.

Vaping Industry Pressure Triggers Conflict

The central conflict erupted after President Trump met directly with an R.J. Reynolds executive in early May 2026, who lobbied for FDA approval of flavored e-cigarettes. Trump subsequently pressured Makary to approve fruit-flavored vaping products, which the commissioner initially resisted on public health grounds. The FDA ultimately approved these products on May 6, but the damage to Makary’s standing was already done. This sequence reveals a troubling pattern where corporate lobbyists gain direct presidential access to override the scientific judgment of federal health officials—a practice that undermines the independence agencies need to protect American consumers from potentially harmful products.

Broader FDA Controversies Under Makary

Beyond vaping disputes, Makary faced criticism from the pharmaceutical industry over his handling of drug approvals. His FDA unexpectedly rejected Replimune’s RP1 melanoma therapy, frustrating biotech companies and investors who believed the treatment met approval standards. Additionally, his deputy commissioner and biologics chief, Vinay Prasad, resigned last week amid reported infighting and policy disagreements. White House advisers, influenced by pharmaceutical industry concerns, reportedly told Trump that Makary had become a “problem” blocking the administration’s agenda. These developments suggest pressure from wealthy corporate interests seeking faster approvals, regardless of safety considerations that protect everyday Americans.

Pattern of Political Interference in Science

This situation mirrors Trump’s first-term conflicts with FDA leadership over COVID-19 vaccines and hydroxychloroquine, when political considerations overrode scientific protocols. What particularly concerns citizens on both left and right is the apparent ease with which industry executives secure presidential meetings to advocate for products affecting public health, while ordinary Americans struggle to have their voices heard. Makary, a Johns Hopkins surgeon and researcher appointed in March 2025 to create a “smarter FDA,” now finds his science-based approach at odds with political expedience. Whether one supports Trump’s policies or opposes them, the spectacle of government agencies being reshaped by corporate lobbying rather than public interest erodes trust in institutions meant to protect all Americans.

The uncertainty surrounding Makary’s status creates practical problems beyond political drama. Pending drug approvals remain in limbo, affecting patients waiting for potentially life-saving treatments. Vaping industry stocks fluctuate with each contradictory signal from the White House. Meanwhile, potential successor candidates like deputy commissioner Kyle Dantas or former Trump administration officials Stephen Hahn and Brett Pritt reportedly await word on their futures. Americans deserve better than this revolving door of leadership driven by whoever has the president’s ear on any given day, rather than by competent officials committed to their scientific mission and the public good.